Login
Israel-Hamas Conflict
Military
Social Media
Protestors
World Cup
Donald Trump
Soccer
War
Benjamin Netanyahu
Rugby
Wrestling
Instagram
WWE
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Breakthrough Lymphoma Treatment Achieves Remarkable 87% Response Rate in Advanced DLBCL Patients

Summary by stocktitan.net
New epcoritamab combination therapy demonstrates powerful efficacy for resistant lymphoma, with 65% complete response rate. See detailed trial outcomes and safety data.

5 Articles

All
Left
Center
1
Right
The Daily NewsThe Daily News
+3 Reposted by 3 other sources
Center

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Jun 15, 2025-

Read Full Article
stocktitan.netstocktitan.net

Breakthrough Lymphoma Treatment Achieves Remarkable 87% Response Rate in Advanced DLBCL Patients

New epcoritamab combination therapy demonstrates powerful efficacy for resistant lymphoma, with 65% complete response rate. See detailed trial outcomes and safety data.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Daily News broke the news in on Sunday, June 15, 2025.
Sources are mostly out of (0)

Similar News Topics

Denmark

Denmark

News
For You
SearchBlindspotLocal